by John Conrad | Dec 19, 2024 | Member News
Chicago-based Xentria advances Illinois’ position in life sciences innovation through strategic academic partnership* Illinois’ biotechnology sector continues to demonstrate its growing prominence with Xentria, Inc., a Chicago-based clinical-stage...
by John Conrad | Dec 18, 2024 | Capital Pulse
Flow Medical, a startup spun out of UChicago Medicine, has secured $5 million in seed funding, with UCM Ventures making its inaugural investment in the company. The startup, founded by three University of Chicago faculty members, is developing a specialized catheter...
by John Conrad | Dec 18, 2024 | iBIO in the News
iBIO President & CEO John Conrad recently had the pleasure of chatting with Kyle LaHucik to discuss the exciting developments in our biotech ecosystem. Many of you may have already seen his excellent article published yesterday in Endpoints News, which provides a...
by John Conrad | Dec 18, 2024 | iBIO News
As Illinois’ life sciences industry continues its remarkable growth trajectory, iBIO President and CEO John Conrad and iBIO Board Chair Ken Johnson, Senior Vice President of Global Development and Medical Affairs at Xeris Pharmaceuticals, sat down to discuss the...
by John Conrad | Dec 12, 2024 | Member News, NewsBrief
In a significant move addressing one of healthcare’s most pressing challenges, Meitheal Pharmaceuticals has secured exclusive U.S. commercial rights to XENLETA® (lefamulin acetate). The timing couldn’t be more critical: between now and 2050, antibiotic...
